AAPS PharmSciTech

, Volume 11, Issue 3, pp 1193–1201 | Cite as

Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine

Research Article

Abstract

Mortality due to seasonal and pandemic influenza could be reduced by increasing the speed of influenza vaccine production and distribution. We propose that vaccination can be expedited by (1) immunizing with influenza virus-like particle (VLP) vaccines, which are simpler and faster to manufacture than conventional egg-based inactivated virus vaccines, and (2) administering vaccines using microneedle patches, which should simplify vaccine distribution due to their small package size and possible self-administration. In this study, we coated microneedle patches with influenza VLP vaccine, which was released into skin by dissolution within minutes. Optimizing the coating formulation required balancing factors affecting the coating dose and vaccine antigen stability. Vaccine stability, as measured by an in vitro hemagglutination assay, was increased by formulation with increased concentration of trehalose or other stabilizing carbohydrate compounds and decreased concentration of carboxymethylcellulose (CMC) or other viscosity-enhancing compounds. Coating dose was increased by formulation with increased VLP concentration, increased CMC concentration, and decreased trehalose concentration, as well as increased number of dip coating cycles. Finally, vaccination of mice using microneedles stabilized by trehalose generated strong antibody responses and provided full protection against high-dose lethal challenge infection. In summary, this study provides detailed analysis to guide formulation of microneedle patches coated with influenza VLP vaccine and demonstrates effective vaccination in vivo using this system.

KEY WORDS

coating formulation influenza intradermal immunization microneedle virus-like particle vaccine 

Notes

Acknowledgments

This work was supported in part by NIH grants R01-EB006369 (M.R.P.) and U01-AI0680003 (R.W.C.), SERCEB (R.W.C) and the Georgia Research Alliance Program grant (S.M.K). We thank Dr. Vladimir Zarnitsyn for microneedle fabrication, Dr Young-Bin Choy for SEM imaging, and Dr. Mark Allen for use of laser microfabrication facilities. M.R.P. serves as a consultant and is an inventor on patents licensed to companies developing microneedle-based products. These possible conflicts of interest have been disclosed and are being managed by Georgia Tech and Emory University.

References

  1. 1.
    Ellebedy AH, Webby RJ. Influenza vaccines. Vaccine. 2009;27:D65–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Hoelscher M, Gangappa S, Zhong WM, Jayashankar L, Sambhara S. Vaccines against epidemic and pandemic influenza. Expert Opin Drug Deliv. 2008;5:1139–57.CrossRefPubMedGoogle Scholar
  3. 3.
    Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis. 2006;194:S111–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21:1776–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Centers for Disease Control and Prevention. Use of influenza A (H1N1) 2009 monovalent vaccine, recommendations of the Advisory Committee on Immunization Practices. Morb Mort Wkly Rep. 2009;58:1–8.Google Scholar
  6. 6.
    Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362:1733–45.CrossRefPubMedGoogle Scholar
  7. 7.
    Palache AM. Influenza vaccines—a reappraisal of their use. Drugs. 1997;54:841–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Jennings GT, Bachmann MF. Coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521–36.CrossRefPubMedGoogle Scholar
  9. 9.
    Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003;11:438–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009:369-93.Google Scholar
  11. 11.
    Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, Nyam K, et al. Macroflux (R) microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm Res. 2002;19:63–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Andrianov AK, DeCollibus DP, Gillis HA, Kha HH, Marin A, Prausnitz MR, et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci USA. 2009;106:18936–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis. 2010;201:190–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Koutsonanos DG, Martin MdP, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE. 2009;4:e4773.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhu QY, Zarnitsyn VG, Ye L, Wen ZY, Gao YL, Pan L, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci USA. 2009;106:7968–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine. 2009;27:454–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med. 2002;8:415–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Debenedictis C, Joubeh S, Zhang GY, Barria M, Ghohestani RF. Immune functions of the skin. Clin Dermatol. 2001;19:573–85.CrossRefPubMedGoogle Scholar
  19. 19.
    Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine. 2007;25:659–63.CrossRefPubMedGoogle Scholar
  20. 20.
    Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, et al. Serum antibody responses after intradermal vaccination against influenza. New Engl J Med. 2004;351:2286–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. New Engl J Med. 2004;351:2295–301.CrossRefPubMedGoogle Scholar
  22. 22.
    Hinman AR, Orenstein WA, Santoli JM, Rodewald LE, Cochi SL. Vaccine shortages: history, impact, and prospects for the future. Annu Rev Public Health. 2006;27:235–59.CrossRefPubMedGoogle Scholar
  23. 23.
    Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198:650–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26:3197–208.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Improved influenza vaccination in the skin using vaccine coated-microneedles. Vaccine. 2009;27:6932–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS ONE. 2009;4:e7152.CrossRefPubMedGoogle Scholar
  27. 27.
    Bal SM, Caussin J, Pavel S, Bouwstra JA. In vivo assessment of safety of microneedle arrays in human skin. Eur J Pharm Sci. 2008;35:193–202.CrossRefPubMedGoogle Scholar
  28. 28.
    Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human volunteers. Clin J Pain. 2008;24:585–94.CrossRefPubMedGoogle Scholar
  29. 29.
    Haq MI, Smith E, John DN, Kalavala M, Edwards C, Anstey A, et al. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices. 2008;11:35–47.CrossRefGoogle Scholar
  30. 30.
    Quan FS, Huang CZ, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81:3514–24.CrossRefPubMedGoogle Scholar
  31. 31.
    Ludwig K, Korte T, Herrmann A. Analysis of delay times of hemagglutinin-mediated fusion between influenza-virus and cell-membranes. Eur Biophys J. 1995;24:55–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007;117:227–37.CrossRefPubMedGoogle Scholar
  33. 33.
    Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 2010;142:187–95.CrossRefPubMedGoogle Scholar
  34. 34.
    Vyas GN, Shulman NR. Hemagglutination assay for antigen and antibody associated with viral hepatitis. Science. 1970;170:332–3.CrossRefPubMedGoogle Scholar
  35. 35.
    Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine. 2006;24:6110–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen XF, Prow TW, Crichton ML, Jenkins DWK, Roberts MS, Frazer IH, et al. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release. 2009;139:212–20.CrossRefPubMedGoogle Scholar
  37. 37.
    Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang S-M. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008;26:3352–61.CrossRefPubMedGoogle Scholar
  38. 38.
    Amorij JP, Huckriede A, Wischut J, Frifflink HW, Hinrichs WLJ. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25:1256–73.CrossRefPubMedGoogle Scholar
  39. 39.
    Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol. 2008;82:1350–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Amorij JP, Meulenaar J, Hinrichs WLJ, Stegmann T, Huckriede A, Coenen F, et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze drying. Vaccine. 2007;25:6447–57.CrossRefPubMedGoogle Scholar
  41. 41.
    de Jonge J, Amorij JP, Hinrichs WLJ, Wiischuta J, Huckriedea A, Frijlinkb HW. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur J Pharm Sci. 2007;32:33–44.CrossRefPubMedGoogle Scholar
  42. 42.
    Maa YF, Ameri M, Shu C, Payne LG, Chen DX. Influenza vaccine powder formulation development: spray freeze drying and stability evaluation. J Pharm Sci. 2004;93:1912–23.CrossRefPubMedGoogle Scholar
  43. 43.
    Steinhauer DA. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology. 1999;258:1–20.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  1. 1.School of Chemical and Biomolecular EngineeringGeorgia Institute of TechnologyAtlantaUSA
  2. 2.Department of Microbiology and ImmunologyEmory University School of MedicineAtlantaUSA

Personalised recommendations